You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

338 Results
Drug
Other Name(s): Trisenox®
Updated
Oct 2025
Drug
Other Name(s): Zinecard®
Updated
Oct 2025
Regimen
Cancer Type:
Gastrointestinal, 
Rectal
Intent: Neoadjuvant
Updated
Oct 2025
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Intent: Adjuvant, Curative
New
Oct 2025
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Relapsed or Refractory Multiple Myeloma
New Drug Funding Program
    Daratumumab - In Combination with Bortezomib and Dexamethasone for Relapsed Multiple Myeloma
ODB - General Benefit
    dexamethasone
Updated
Oct 2025
Drug
Other Name(s): Tibsovo®
Updated
Oct 2025
Drug
Other Name(s): Columvi®
Updated
Oct 2025
Drug
Other Name(s): Tecvayli®
Updated
Oct 2025
Drug
Other Name(s): Epkinly™
Updated
Oct 2025
Drug
Other Name(s): Kimmtrak®
Updated
Oct 2025
Drug
Other Name(s): Ibrance™
Updated
Oct 2025
Drug
Other Name(s): Truqap™
Updated
Oct 2025

Pages